Last updated: September 8, 2026
The four-drug regimen is marketed in the United States as Symtuza, a once-daily fixed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide fumarate equivalent to tenofovir alafenamide 10 mg. Janssen markets the product, while Gilead Sciences supplies or owns key components and intellectual property associated with cobicistat, emtricitabine, and tenofovir alafenamide.
Symtuza has durable commercial value because it combines a high-barrier protease inhibitor with the newer tenofovir alafenamide formulation. Its main constraints are the continuing shift toward integrase inhibitor regimens, limited public disclosure of product-level revenue, and eventual generic risk to the fixed-dose combination and its individual ingredients.
Public filings through fiscal year 2023 and FDA information available through June 2024 indicate:
| Metric |
Assessment |
| Product |
Symtuza |
| Active ingredients |
Darunavir, cobicistat, emtricitabine, tenofovir alafenamide |
| FDA approval |
July 17, 2018 |
| Indication |
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg |
| Dosing |
One tablet once daily with food |
| Product owner and marketer |
Janssen Sciences Ireland UC and affiliated Janssen entities |
| Strategic component suppliers |
Gilead Sciences and Janssen |
| Biosimilar exposure |
None; Symtuza is a small-molecule product |
| Primary competitive threat |
Single-tablet and two-drug integrase inhibitor regimens |
| Generic exposure |
Medium term, concentrated in individual-component and fixed-dose-combination patents |
| Product-level revenue disclosure |
Not separately reported by Janssen or Gilead |
What is Symtuza and how does the four-drug regimen work?
Symtuza is a complete antiretroviral regimen for HIV-1 treatment. Darunavir inhibits HIV protease and has a relatively high genetic barrier to resistance. Cobicistat inhibits CYP3A-mediated metabolism and raises darunavir exposure. Emtricitabine and tenofovir alafenamide inhibit HIV reverse transcriptase.
The formulation’s commercial rationale is the combination of:
- Darunavir’s resistance profile.
- Once-daily dosing.
- Lower circulating tenofovir exposure than tenofovir disoproxil fumarate.
- A single-tablet format for patients who require a boosted protease inhibitor.
The FDA label limits use in patients without darunavir-associated resistance substitutions or prior darunavir treatment failure. Symtuza is not interchangeable with other antiretroviral tablets because the four-component ratio, pharmacokinetic booster, and food requirement are product-specific. [1]
How does Symtuza compare with competing HIV drugs?
Symtuza competes primarily with Biktarvy, Genvoya, Odefsey, Triumeq, Dovato, Juluca, and generic multi-tablet regimens.
| Product |
Core regimen |
Principal commercial position |
Relative Symtuza impact |
| Symtuza |
Darunavir/cobicistat/emtricitabine/TAF |
High-barrier boosted protease inhibitor, single tablet |
Reference product |
| Biktarvy |
Bictegravir/emtricitabine/TAF |
Broad first-line use and strong tolerability profile |
Major share competitor |
| Genvoya |
Elvitegravir/cobicistat/emtricitabine/TAF |
Earlier-generation single-tablet integrase regimen |
Competes for TAF-based patients |
| Odefsey |
Rilpivirine/emtricitabine/TAF |
Lower-pill-burden regimen for selected patients |
Competes in virologically suppressed patients |
| Triumeq |
Dolutegravir/abacavir/lamivudine |
Established integrase-based regimen |
Competes in treatment-naive and switch markets |
| Dovato |
Dolutegravir/lamivudine |
Two-drug regimen |
Increases pressure on four-drug products |
| Juluca |
Dolutegravir/rilpivirine |
Two-drug maintenance therapy |
Competes in suppressed patients |
Biktarvy has the strongest commercial momentum in the category. Gilead reported Biktarvy product sales of approximately $11.9 billion in 2023, compared with approximately $2.3 billion for Descovy, another TAF-containing product. [2] These figures demonstrate the commercial preference for integrase-based regimens, but they do not represent Symtuza revenue.
What is the FDA regulatory status of Symtuza?
Symtuza received FDA approval in July 2018 for adults and pediatric patients weighing at least 40 kg with HIV-1 infection who have no history of treatment failure and no known resistance to darunavir, emtricitabine, or tenofovir.
The product’s regulatory value comes from its complete-regimen status. Physicians can prescribe one tablet without adding a separate nucleoside backbone or pharmacokinetic enhancer. Its limitations include the need for administration with food, CYP3A drug-interaction management, renal and hepatic considerations, and restrictions based on resistance history. [1]
FDA approval of Symtuza did not create a new active moiety for each component. Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide had prior regulatory histories. The approval therefore created combination-product exclusivity and clinical-data protection rather than a new chemical-entity position comparable to a novel standalone molecule.
What is the Orange Book status of Symtuza?
Symtuza is listed in the FDA Orange Book as a prescription drug with patent information and method-of-use information associated with the fixed-dose product. The Orange Book framework permits an abbreviated new drug application applicant to certify against listed patents under Paragraphs I through IV.
The relevant patent categories generally include:
- Composition and fixed-dose combination claims.
- Pharmaceutical composition claims covering the four active ingredients.
- Dosage and administration claims.
- Treatment claims for HIV infection.
- Formulation and stability claims.
- Patents directed to tenofovir alafenamide, cobicistat, or combination use.
The key commercial distinction is that expiration of an individual ingredient patent does not automatically authorize a generic version of Symtuza. A generic applicant must address the patents listed against the fixed-dose product and satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.
When does Symtuza lose exclusivity?
Symtuza’s principal statutory exclusivity period from the 2018 approval has already expired. The remaining barrier is patent protection rather than regulatory exclusivity.
There is no single expiration date for the entire commercial franchise. The relevant dates differ by patent family and by the claims asserted against a particular ANDA. Some foundational patents covering older ingredients have expired or are approaching expiration, while later combination, formulation, and prodrug patents can extend protection into the late 2020s or beyond.
A practical exclusivity timeline is:
| Period |
Commercial significance |
| 2018 |
FDA approval of Symtuza |
| 2018-2021 |
Primary combination-product regulatory exclusivity period |
| Early 2020s |
Greater exposure to ANDA development and Paragraph IV certifications |
| Mid-to-late 2020s |
Potential generic entry window, depending on patent litigation and settlement terms |
| After final enforceable patent expiry |
Broadest risk of fixed-dose generic substitution |
The exact launch date depends on the last enforceable patent, any pediatric extension, patent-term adjustment, litigation outcome, and settlement restrictions. Product-level statements that assign one universal expiration date to Symtuza are incomplete.
What patents protect darunavir, cobicistat, emtricitabine, and tenofovir alafenamide?
Protection is layered across four active ingredients and the commercial combination.
Darunavir
Darunavir has a mature patent estate centered on the protease inhibitor molecule, salts, formulations, and treatment methods. Its foundational protection is older than the Symtuza product and has less strategic value than later fixed-dose and formulation claims.
Darunavir’s commercial protection is also affected by the existence of Prezista, standalone darunavir, and other darunavir-containing products. Generic entry against darunavir alone does not necessarily permit substitution for Symtuza because cobicistat, emtricitabine, and TAF remain part of the fixed-dose product’s regulatory and patent profile.
Cobicistat
Cobicistat is a pharmacokinetic enhancer developed as an alternative to ritonavir. Its patent value is linked to the molecule, pharmaceutical compositions, and use with antiretroviral agents. Cobicistat is also present in Genvoya and other products, making its intellectual property relevant to more than one commercial franchise.
Emtricitabine
Emtricitabine is a mature nucleoside reverse transcriptase inhibitor. Its standalone composition protection is largely exhausted, but it remains commercially important as part of branded fixed-dose combinations. Combination claims can retain value after the underlying molecule becomes generic.
Tenofovir alafenamide
TAF is the most commercially important newer component in Symtuza. It was designed to deliver tenofovir with lower plasma exposure than tenofovir disoproxil fumarate. TAF-related patents cover the prodrug, salts, compositions, formulations, and combinations with other antiretrovirals.
TAF patent rights also support Biktarvy, Genvoya, Odefsey, Descovy, and other Gilead products. This creates portfolio leverage but also concentrates litigation and licensing exposure around a limited number of major patent families.
Which companies are challenging Symtuza patents?
Publicly disclosed generic challenges have focused on HIV combination products and the underlying ingredient patents. The principal potential challengers are large generic manufacturers with existing antiretroviral manufacturing and regulatory capabilities, including Teva, Viatris, Cipla, Lupin, Hetero, and Aurobindo-affiliated entities.
A Paragraph IV challenge would require the applicant to assert that the relevant patent is invalid, unenforceable, or not infringed. The patent holder can file an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months unless the litigation is resolved earlier. [3]
The commercial value of a challenge depends on whether it targets:
- Darunavir alone.
- Cobicistat alone.
- A TAF-containing product.
- The complete Symtuza fixed-dose combination.
- A method-of-use or formulation patent.
A challenge to one ingredient does not necessarily create a launch path for the full product. The strongest generic strategy is a coordinated challenge to the fixed-dose product and the major ingredient patents.
What patent litigation and settlement risks affect Symtuza?
The main litigation risk is an ANDA patent case in the U.S. District Court for the District of New Jersey, where many Janssen pharmaceutical patent disputes are filed. The primary issues would be claim construction, obviousness, written description, enablement, infringement, and patent-term calculations.
Potential settlement structures include:
- A license with a fixed future launch date.
- An authorized-generic arrangement.
- A covenant not to sue for selected dosage forms.
- Restrictions limited to specific patents or indications.
- A launch date tied to an appellate decision or patent invalidation.
Settlement terms are commercially material because a generic may enter before the final expiration of every listed patent if the settlement grants a license to the remaining claims. Publicly available information through June 2024 does not establish a broad, market-wide Symtuza settlement that eliminates all generic risk.
How strong is the patent estate for Symtuza?
The estate is moderate to strong in the near term but weaker over the long term.
Its strengths are:
- Multiple active pharmaceutical ingredients with separate patent histories.
- TAF-related composition and formulation protection.
- Fixed-dose combination claims.
- A differentiated boosted protease inhibitor regimen.
- Regulatory complexity that raises development costs for generic applicants.
Its weaknesses are:
- The product combines mostly mature antiretroviral components.
- HIV treatment guidelines increasingly favor integrase inhibitors.
- Individual components may become available from generic suppliers.
- Bioequivalence and substitution economics may favor separate generic tablets once the relevant patents expire.
- Symtuza lacks the exclusivity duration associated with a newly discovered chemical entity.
The estate is therefore more defensible as a branded niche product than as a long-duration monopoly platform.
What is the financial trajectory for Symtuza?
Janssen does not separately disclose Symtuza revenue in its public annual reports. The product is reported within broader infectious-disease or HIV portfolios, which limits precise revenue attribution.
The financial trajectory has four stages:
Launch and rapid adoption
After its 2018 launch, Symtuza gained share among patients requiring darunavir and among patients switching from multi-tablet boosted protease inhibitor regimens. Its single-tablet format and TAF backbone supported adoption.
Portfolio expansion
Symtuza broadened Janssen’s HIV portfolio beyond standalone Prezista and older darunavir combinations. The product also allowed Janssen to participate in the TAF-based commercial segment without relying exclusively on separate tablets.
Mature-market pressure
The product now competes against Biktarvy and other integrase-based regimens with strong guideline positioning. The overall HIV market remains financially attractive, but growth is concentrated in newer products and in long-term treatment markets with high patient retention.
Late-life erosion
Revenue pressure will increase when generic manufacturers obtain approval for darunavir, cobicistat, TAF, and the fixed-dose combination. Erosion may occur in stages rather than through an immediate collapse:
- Generic individual components enter.
- Multi-tablet generic regimens gain formulary access.
- A generic fixed-dose combination launches.
- Payers impose substitution or step-editing requirements.
- Symtuza retains selected patients requiring its specific regimen or prescriber familiarity.
For Janssen, Symtuza’s revenue exposure is meaningful at the portfolio level but is not separately quantifiable from public filings. For Gilead, the product has strategic relevance because it uses TAF, emtricitabine, and cobicistat-related technology, but Biktarvy and Descovy are much larger disclosed revenue drivers. [2]
What generic launch scenarios exist for Symtuza?
| Scenario |
Timing |
Market effect |
| No successful Paragraph IV challenge |
After final patent expiry |
Delayed but potentially concentrated erosion |
| Early litigation settlement |
Contractual launch date |
Predictable erosion with possible authorized-generic competition |
| Court invalidation of key TAF or combination patent |
Before all listed patents expire |
Accelerated launch and substantial price pressure |
| Generic individual ingredients only |
Before fixed-dose approval |
Gradual erosion through multi-tablet substitution |
| Full fixed-dose generic approval |
After FDA approval and patent clearance |
Highest substitution and pricing risk |
The most probable commercial pattern is a gradual decline rather than an immediate loss of all sales. Physicians may preserve Symtuza for patients with resistance concerns, prior treatment complexity, or a preference for darunavir-based therapy. Payers will favor lower-cost alternatives where clinical guidelines permit substitution.
How does geographic coverage affect market value?
The United States is the most important jurisdiction for patent monetization because of high branded drug prices, Orange Book listing, and ANDA litigation. Europe has a more fragmented reimbursement structure and greater exposure to national tendering and generic substitution.
Patent protection varies by country. Key territories include:
- United States.
- European Union member states.
- Canada.
- Japan.
- Australia.
- Brazil.
- China.
- India.
The effective commercial life in each country depends on national patent validation, supplementary protection certificates, regulatory data protection, reimbursement decisions, and local generic manufacturing. India is particularly relevant to generic supply because several major antiretroviral manufacturers are based there, although patent validity and licensing requirements vary by product and jurisdiction.
What manufacturing and intellectual-property barriers affect generic entry?
Generic manufacturers must reproduce a technically complex product containing four active ingredients with different physical and chemical properties. The principal barriers are:
- Demonstrating bioequivalence for a four-component fixed-dose tablet.
- Controlling TAF stability and degradation products.
- Managing cobicistat-related drug-interaction labeling.
- Matching dissolution and food-effect characteristics.
- Securing reliable API supply for darunavir and TAF.
- Resolving patents covering the combination, formulation, and manufacturing process.
- Meeting FDA requirements for a complete fixed-dose regimen.
These barriers increase development cost and make a large generic launch more likely among established HIV manufacturers than among small generic companies.
Key Takeaways
- Symtuza is the branded fixed-dose combination of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide.
- Janssen markets the product, while Gilead’s TAF, emtricitabine, and cobicistat-related assets are strategically relevant.
- The product’s FDA regulatory exclusivity has ended; patent protection remains the principal barrier.
- Symtuza has no biosimilar risk because it is a small-molecule product.
- Generic exposure will arise through both individual-component approvals and a potential fixed-dose combination.
- Biktarvy is the strongest commercial competitor and has materially greater disclosed revenue.
- Janssen does not separately report Symtuza sales, preventing a precise product-level revenue estimate.
- The patent estate is strongest around TAF, combination, formulation, and method-of-use claims.
- Generic erosion is likely to be gradual unless a key combination or TAF patent is invalidated early.
- The product retains value in patients requiring a high-barrier, darunavir-based single-tablet regimen.
FAQs
Is Symtuza the same as Prezista?
No. Prezista contains darunavir alone, while Symtuza contains darunavir, cobicistat, emtricitabine, and TAF in one tablet.
Can a generic darunavir tablet replace Symtuza?
No. A generic darunavir product does not provide cobicistat, emtricitabine, or TAF and is not automatically substitutable for Symtuza.
Does Symtuza have biosimilar competition?
No. Biosimilar rules apply to biological products. Symtuza is regulated as a small-molecule drug and faces generic, not biosimilar, competition.
Is Symtuza preferred over Biktarvy for most newly diagnosed patients?
Generally, integrase inhibitor regimens such as Biktarvy have stronger first-line commercial and guideline positioning. Symtuza remains relevant where darunavir’s resistance barrier or prior-treatment history is important.
What is the biggest long-term value driver for Symtuza?
The principal value driver is continued retention of patients who require or prefer a darunavir-based complete regimen before generic fixed-dose or component competition becomes widely available.
References
-
U.S. Food and Drug Administration. (2024). Symtuza prescribing information. FDA.
-
Gilead Sciences, Inc. (2024). 2023 annual report. Gilead Sciences.
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Johnson & Johnson. (2024). 2023 annual report. Johnson & Johnson.
-
U.S. Food and Drug Administration. (2024). HIV antiviral drugs and treatment information. FDA.
